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Summary
Tumor stimulates specific innate and acquired immune mechanisms. Main carriers of body’s immune response to 
 tumor are T lymphocytes and main mechanism is killing of tumor cells by cytotoxic T lymphocytes CD8 +. In some cases, 
immune system can also have a protumor role, which is a paradox, given that it is known that the inflammatory state pro-
motes tumor growth. One of the major characteristics of tumors is the evading of immune response, in particular by mecha-
nisms of inhibition of active antitumor immune response via two major physiological inhibitory signals, CTLA-4 and PD1 / 
PDL1. Blockade of these checkpoints, that are T cell inhibitory mechanisms, has recently yielded best results in an immuno-
therapy approach to cancer treatment. Immune infiltrate in the tumor, as evidence of existence of an active intrinsic response 
of the organism, is heterogeneous, and composition often differs between different tumors and tumor cells, and mainly 
 divides into two main cell lines: lymphoid and myeloid. On type of cell lines in the immune infiltrate and their activation 
and orientation depends the clinical response in different tumors. It is well known that immune infiltrate, especially tumor-
infiltrating lymphocytes (TILs), can be predictive of response to therapy and have a prognostic role. In some solid tumors 
they are a good sign, while in some they signal worse prognosis. Numerous studies have evaluated role of lymphocytic in-
filtrate in breast cancer (BC) and, based on this knowledge, first consensus on standardization of TILs evaluation in solid 
tumors has been established on the BC model. Prognostic role of TILs in triple-negative breast cancer has received the most 
attention.
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Despite being produced by the cells of the 
host organism, the tumor cells for the immune 
system represent a foreign body and the immune 
system responds to them. Tumor immunogenici-
ty, ie the ability to elicit an immune response of 
the organism, is generated by tumor antigens (1). 
There are several categories of tumor antigens. 
Most of these are protein neo-antigens resulting 
from sporadically mutated genes, (so-called pas-
senger mutations), and less often due to mutations 
in oncogenes or tumor suppressor genes involved 
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in oncogenesis (so-called driver mutations). An-
other type are oncoviral antigens, that is, products 
of oncogenic viruses, which can elicit a specific T 
cell response. The third category includes overex-
pressed cellular proteins. These are the products 
of genes that are silenced in normal cells and re-
leased in tumor cells or proteins present in normal 
cells but overproduced in the tumor. These are, 
for example, cancer - testis antigens (CTA), such as 
MAGE, an oncogenic variant of the epidermal 
growth factor HER2 / Neu, and differentiation an-
tigens such as CD on lymphoma and leukemia 
cells. Tumor antigens also include various alterat-
ed glycolipids and glycoproteins, as well as on-
cofetal antigens alpha feto protein (AFP) and car-
cinoembryonic antigen (CEA) (1,2).
Immune response
The physiological role of the immune system 
is immunosurveillance (1,3), the recognition and 
destruction of clones of transformed cells before 
they grow into a tumor and the killing of tumors. 
Evidence that this surveillance system is needed is 
also the fact that an increased incidence of a num-
ber of tumors appears in an immunocompromised 
organism, but also that is imperfect - the fact that 
also in an immunocompetent organism some tu-
mors escape immune control and develop. Tumor 
stimulates specific innate and acquired immune 
response mechanisms. The main carriers of the 
body’s immune response (1,4) to tumor are T lym-
phocytes and the main mechanism is the killing of 
tumor cells by cytotoxic T lymphocytes CD8 + 
(CTL). CTLs conduct immune surveillance by rec-
ognizing and killing potentially malignant cells 
expressing peptides of tumor antigen origin, pre-
sented in interaction with major histocompatibili-
ty class I (MHC I) molecules. Thus, in order for 
CD8 + CTL to function, the presentation of tumor 
antigens by antigen presenting cells (APC), usu-
ally dendritic cells, is required in MHC I. Also, 
APC express costimulatory molecules, and those 
and simultaneously activated helper T lympho-
cytes send major signals for differentiation of na-
ive CD8 + T lymphocytes into competent CTLs. 
CD4 + helper T lymphocytes contribute to the an-
titumor immune response in many ways: Th1 cells 
enhance the CD8 + T cell response and activate 
macrophages by secreting TNF and IFN γ, which 
enhances MHC I. In addition to T cells, the host 
organism often produces antibodies against tu-
mor antigens, but the significance of them is not 
completely clear. Natural killer (NK) cells are ca-
pable of killing different types of tumor cells. Tu-
mor cells become susceptible to NK cell killing 
when MHC I expression is reduced or the expres-
sion of ligands that bind to activating NK cell re-
ceptors is increased, and cytokines such as IL-2 
and IL-15 stimulate NK cells. Depending on the 
state of activity, macrophages can inhibit or pro-
mote tumor growth. Classic M1 activated macro-
phages kill various types of tumor cells. They are 
activated by the described IFN γ production pro-
cess by Th1 helper CD4 + lymphocytes, and it is 
not clear how they are activated by tumors (1,4,5).
Protumor role of immunity
In some cases, the immune system may also 
have a protumor role. It has long been known that 
chronic inflammation is a risk factor for the devel-
opment of many tumors (1,6) although the exact 
mechanism of this cascade is unknown. Among 
immune cells, cells of innate immunity are consid-
ered the key culprits for protumor effects. Tumor-
associated macrophages (TAM) of the alternative-
ly activated M2 phenotype, as well as some other 
cells, are the source of vascular endothelial growth 
factor (VEGF), which promotes angiogenesis as 
well as extracellular space-modifying enzymes, 
thereby supporting tumor growth and spread. By 
accumulating free radicals, cells of innate immu-
nity contribute to DNA damage and mutations, 
which lead to malignant alteration, and by secret-
ing soluble factors such as NFκB support the pro-
gression and survival of tumor cells. Alternatively 
activated M2 macrophages and myeloid-derived 
immunosuppressive cells, MDSC, indirectly sup-
port tumor growth by suppressing effective anti-
tumor immunity. In response to the tumor, den-
dritic cells can condition the differentiation of CD4 
+ into anti-inflammatory Th2 cells and T regula-
tory cells, which suppress the tumor-killing im-
mune response and support the development of 
M2 and other protumor cell lines. The described 
protumor effects of the anti-inflammatory mecha-
nisms of the immune system are somewhat para-
doxical, since it is known, as described above, that 
the inflammatory state promotes tumor growth, 
and therefore finding a balance between the de-




Immunoediting and tumor escape
One of the major characteristics of tumors is 
evading the immune response. This suggests that 
the immune control of the host organism over the 
tumor is only one of the possible variants, that is, 
the phase in the interaction with the tumor, and 
that the interaction of the tumor and the host is 
best described through the process of immunoed-
iting. Immunoediting (7) involves the interaction 
of a tumor and host organism, which takes place 
in three stages. The first phase is the elimination 
phase, a stage where the mechanisms of immune 
control are adequately functional and eliminate 
potentially malignant altering cells and tumors. In 
the equilibrium phase, the coexistence of the host 
and the tumor is achieved, that is, the host im-
mune system does not eradicate the tumor cells 
although they do not progress but are dormant. 
The third phase is the tumor escape phase from 
immune surveillance. The mechanisms of avoid-
ance of immune surveillance by tumors are gener-
ally categorized as either active inhibition of the 
antitumor immune response or loss of antigens 
that stimulate these immune responses (1). Inhibi-
tion of an active antitumor immune response is ac-
complished in several ways: by the interaction of 
inhibitory molecules on the T cell surface and 
APC, which otherwise have the function of pre-
venting autoimmune reactions, with ligands, or 
cofactor molecules on the tumor surface, then sup-
pressing the antitumor response by secreted mol-
ecules, such as TGF β, by producing regulatory T 
cells that are actually immunosuppressive in na-
ture and by accumulating the described immature 
MDSC, a heterogeneous group of cells, such as 
dendritic, monocytes, and neutrophils that sup-
press innate immunity and T-cell-mediated anti-
tumor immune mechanisms, either by secretion of 
immunosuppressive cytokines or by stimulating 
the accumulation of regulatory T cells. The best 
known inhibitory signaling pathways of T cells 
and APC, which naturally serve mainly to avoid 
and control autoimmune responses, and in the 
case of tumor escape are the most commonly 
abused pathways to immune surveillance are the 
signaling pathways via CTLA - 4 and PD - 1 (1,7,8). 
Beside of the described mechanisms of inhibition 
of the active antitumor immune response, the 
avoidance of immune control of the tumor also al-
lows the loss of expression of tumor antigens, ie 
the decrease in immunogenicity, which is usually 
accompanied by the decreased activity of antigen 
presenting molecules (1).
Immunotherapy approaches
Immunotherapy is defined as any attempt to 
use any component of the immune system to en-
hance an intrinsic host response to a tumor (9). 
There are two main principles in the immunother-
apy approach: both innate and acquired immuni-
ty are involved in the fight against tumors, by 
mechanisms similar to those used to fight external 
pathogens, and tumor oncogenesis and progres-
sion occur through the selection and outgrowth of 
tumor cells with reduced immunogenicity, and 
with the creation of an immunosuppressive mi-
croenvironment (10). Therefore, therapeutic strat-
egies have focused on stimulating both immune 
mechanisms, to induce tumor cell death. These 
strategies include therapy with various cytokines, 
growth factors, and immunomodulatory agents, 
impact on the tumor microenvironment, passive 
immunotherapy with monoclonal antibodies, vac-
cination with tumor antigens, adoptive cell thera-
py with antitumor T cells, and blockade of check-
points (T cell inhibitory pathways). Blockade of 
checkpoints, or T cell inhibitory mechanisms, has 
recently yielded the best results in an immuno-
therapy approach to cancer treatment and gave 
some hope that acting on the immune system in 
the fight against tumors would surely bring about 
solutions that could not have been hoped for in 
the era of classic nonselective cytotoxic therapy. 
Checkpoint inhibitors have been developed and 
proven in preclinical and more recently phase I, II, 
and III clinical trials and approved in the treat-
ment of numerous solid tumors and hemoblasto-
ses (11). They act on the principle of inhibiting in-
hibition, mainly in two ways: by interfering with 
the inhibitory CTLA-4 pathway and interfering 
with the PD-1 / PDL-1 inhibitory pathway. By 
binding to a T cell receptor in one case, a costimu-
latory molecule in the second case, or a ligand on 
a tumor cell in the third case, inhibitors, which are 
monoclonal antibodies in structure, harbor inhibi-
tory molecules and thus release T cell mechanisms 
of previous inhibition and allow active antitumor 
response, which was missing (10). Pembrolizum-
ab (12) and atezolizumab (13) have shown the best 
results in the treatment of breast cancer to date, 
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and their efficacy is most significant in the treat-
ment of TNBC.
TUMOR – INFILTRATING LYMPHOCYTES
The origin, composition  
and role of immune infiltrate in tumor
Tumor is a complex system, composed of two 
main components: tumor cells and stromal com-
partment. The stromal compartment is composed 
of normal host cells and tissue, such as fibroblasts 
and vasculature cells, nerves, and extracellular 
matrix molecules, which support the biochemical 
and structural environment that ensures tumor 
survival (10). Immune cells, or immune infiltrate, 
are one of the major host cell lines in this stromal 
compartment. The immune infiltrate in a tumor is 
heterogeneous, and the composition often varies 
among different tumors and tumor sites (14). It is 
mainly divided into two main cell lineages: lym-
phoid and myeloid. Research evidence to date in-
dicates that myeloid leukocyte cells, such as TAM, 
dendritic cells (DC) and MDSC, are primarily re-
sponsible, through the factors they produce, for 
the creation of microenvironment in the direction 
of an immunostimulatory antitumor or tumor-
supporting, and antitumor T cells, by migration 
into such environments can consequently be acti-
vated or suppressed. Conversely, T cells them-
selves regulate macrophage recruitment in the di-
rection of functional M1 or protumor M2, indicat-
ing the importance of intercellular interaction (1). 
Likewise, the type of cell lines in the immune infil-
trate determine the clinical response in different 
tumors (10). Acquired immunity mediated by T 
and B lymphocytes is known to play a key role in 
effective antitumor response, and infiltration by 
cytotoxic CD8 + cells has been shown to be associ-
ated with better response to therapy and survival 
(15). The presence of CD4 + regulatory lympho-
cytes can be prognostically both good and bad 
(10), and of the other cellular subpopulations, 
IFNγ-secreting Th1 cells have been shown to be 
associated with a good prognosis (16) and Th2 
with a decrease in antitumor response (17). The 
presence of Th17 cells, the producer of the proin-
flammatory cytokines IL - 17, has variable effects 
depending on the cytokine environment in which 
they are located, which may also depend on the 
type of tumor and the organ site (1,10). The pre-
cise role of B lymphocytic infiltrate is still not com-
pletely clear. In conclusion, the presence of CD8 +, 
Th1, NK, M1, and DC1 is associated with a good 
antitumor response, and the presence of Th2, M2, 
DC2, MDSC, and FOXP3 + regulatory T lympho-
cytes, which secrete IL - 10 and TGFβ, has immu-
nosuppressive effects (1,10) CTLA-4, PD1 and 
PDL1 are expressed on immune infiltrate cells, es-
pecially cytotoxic CD8 + lymphocytes, as well as 
on tumor cells, which, as previously described, 
are of particular importance today as targets for 
immunotherapy (18).
Tumor – infiltrating lymphocytes  
in solid tumors
As mentioned above, the composition of the 
immune infiltrate may vary, depending on the tu-
mor and the organ site. Also, depending on the 
composition of the immune infiltrate in individual 
tumors, different clinical responses and different 
levels of prognostic value of the immune infiltrate 
have been reported (10,14,19,20). Prognostic role 
of the presence of tumor lymphocytes (TILs) in 
melanoma has long been known, and today mela-
noma is one of the most successfully treated tu-
mors with immunotherapy (21) A number of stud-
ies evaluating TILs in melanoma in different ways, 
using different evaluation methods and tech-
niques (HE, IHC), in primary site and metastatic 
lesions, and most studies have shown an associa-
tion between the presence of lymphocytic infil-
trate and good prognosis and good response to 
therapy (22 129). Similarly, the prognostic poten-
tial of TILs in colorectal cancer has also long been 
known. Particularly interesting is the ability to 
predict tumor MSI (microsatellite instability) by 
simply evaluating HE TILs in the tumor, with 
greater or less precision, which is a marker of 
dMMR (MissMatchRepair deficiency), one of the 
two major pathogenetic pathways of colorectal 
cancer, and that is of prognostic and predictive 
value (23). In addition, TILs have been shown to 
be an independent prognostic factor in all types of 
colorectal cancer, independent of MSI status, as 
well as predictor of response to neoadjuvant ther-
apy in rectal cancer (24). Concerning other tumors 
of the digestive system, studies have been con-
ducted on the role of TILs in gastric, pancreatic 
and hepatocellular carcinoma (22), but at the pres-
ent time without concrete positive results and 
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with the need for larger prospective studies. In the 
group of gynecologic tumors, interest in TILs in 
endometrial cancer is mainly associated with the 
possibility of predicting MSI /dMMR status, simi-
lar to colorectal cancer (22), and encouraging re-
sults have been observed in studies of the role of 
TILs in ovarian cancer, although obvious differ-
ences in the prognostic role of TILs have been ob-
served, depending on the type of cellular infiltrate 
as well as in which compartment they were evalu-
ated (25). In the group of urogenital tumors, the 
results differ from seemingly immunogenic blad-
der cancer, which showed not only prognostic but 
also predictive role of TILs (22), via renal cancer, 
in which some studies clearly highlighted nega-
tive association of TILs and prognosis (22), which 
has been shown to exist due to immunosuppres-
sive cells in the infiltrate (such as T regulatory 
cells), to clearly non-immunogenic prostate can-
cer, whose response to immunotherapy remains 
to be investigated (22). Non-small cell lung cancer 
is considered to be a highly immunogenic tumor, 
given the multitude of mutations detected and the 
resulting genomic instability and neo-antigen for-
mation, which is why the mechanisms of immune 
response have been of great clinical interest and 
have been well investigated. TILs have been 
shown to be associated with good prognosis, and 
lung cancer is also one of the tumors with excel-
lent results in immunotherapy treatment (26,27). 
The role of TILs has been investigated in a hetero-
geneous group of head and neck tumors as well as 
in brain tumors (22), and it seems that in the fu-
ture a more accurate, simple and standardized 
methodology, first developed with breast cancer 
and subsequently reproduced in the other men-
tioned tumor sites, will be used to evaluate the 
clinical value of TILs also in other solid tumors.
Tumor – infiltrating lymphocytes  
in breast cancer
Numerous studies have evaluated the value 
of lymphocytic infiltrate in breast cancer (BC) and, 
based on this knowledge, the first consensus on 
the standardization of TILs evaluation in solid tu-
mors has been established on the BC model (28). 
Various evaluation methods have been used in 
TILs studies in BC, from HE, IHC to molecular 
methods of gene expression (29-31). Most relevant 
studies are retrospective TILs analyzes on samples 
from large prospective cohort studies conducted 
in either a population of patients with early or lo-
cally advanced, luminal, HER2-positive or triple 
negative breast cancer (TNBC), who have investi-
gated the effect of some chemotherapy approach, 
in adjuvant or neoadjuvant setting, on tumor tis-
sue specimens obtained by core biopsy or com-
plete specimens obtained operatively, as well as in 
paired specimens of primary tumor and metastat-
ic site, in case of advanced disease (29,32-37). 
Studies have shown very diverse results, and 
these differences are mainly explained by differ-
ences in the methodology and technology applied, 
the method of evaluation and the selection of infil-
trate sections for evaluation, and the different 
sample sizes on which the evaluation was con-
ducted, which affects the statistical significance of 
the results obtained. Nevertheless, the retrospec-
tive nature of most of the studies, which provided 
the first and crucial information thus far, proved 
to be non-inferior in this case and the results ob-
tained may be considered relevant (38). Most BCs 
show some degree of lymphocytic infiltrate. The 
presence of a higher proportion of TILs was ob-
served in more aggressive cancers, with negative 
endocrine receptors, high grade, basaloid charac-
teristics, and BRCA mutants. Lymphocyte-pre-
dominant type of BC (LPBC) is defined as one in 
which 50-60% of tumor is infiltrated by lympho-
cytes. It is more common among tumors of TNBC 
(20%) or HER2-positive immunophenotype (16%), 
compared to luminal, ER-positive (6%) (39) The 
stromal TILs were mainly evaluated by the HE 
method, which proved to be of the greatest impor-
tance, while the intratumoral TILs played a minor 
role (22,28), which may also be due to limitations 
of the HE method itself, which is why the role and 
significance of the intratumoral TILs are further 
evaluated by IHC. It has been found that evalua-
tion of TILs on core biopsy specimens closely cor-
relates with post-operative specimen analysis and 
that both specimens can be used equally (22). 
Studies using the HE method of evaluating TILs in 
the results correlated highly with studies using 
the IHC method as well as mRNA profiling (22,28-
31). The presence of lymphocytic infiltrate was 
also observed in DCIS specimens, most commonly 
those with HER2 positive, and the percentage ap-
pears to be approximately between that in normal 
breast tissue (where it is low) and that in invasive 
carcinoma (where it is high) (40). Compared to the 
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primary site, lymphocytic infiltrate was less prev-
alent in metastatic lesions, which is consistent 
with the theory of immunoediting and tumor es-
cape from immune control (22,37). In prognostic 
terms, TILs are associated with better disease-free 
survival (DFS) and overall survival (OS) most reli-
ably in TNBC and HER2-positive BC, and no sta-
tistically significant benefit was observed in lumi-
nal tumors (especially in luminal A variant) 
(41,42). Furthermore, when they were prognosti-
cally favorable indicator, TILs showed that for ev-
ery 10% of infiltrate intensification, the risk of dis-
ease recurrence and death decreased by about 10-
20% (34), indicating the need for TILs expression 
as continuous variables (22,28,35). Given that both 
chemotherapy and endocrine therapy exert their 
effects to some extent by immunomodulatory 
mechanisms, it is not surprising that results sug-
gesting predictive role for TILs present in the pre-
therapeutic bioptic sample for response to neoad-
juvant anthracycline therapy, where they have 
been found to be independent predictors of pCR 
(35), or an adjuvant combination of anthracyclines 
and taxanes (32), as well as aromatase inhibitor 
therapy (43), and have been shown to be a good 
predictor of response to trastuzumab therapy (33). 
Thus, the described results undoubtedly demon-
strate the predictive and prognostic role of TILs in 
TNBC and HER2-positive BC, and the clinical val-
ue of evaluating TILs in BC is related to the devel-
opment of predictive risk models, (given the con-
tinuity of the variable), therapeutic decision 
 making for use of adjuvant and neoadjuvant che-
motherapy, first and further lines of treatment, 
and with the highly interesting benefit of immu-
notherapy today.
Tumor – infiltrating lymphocytes  
in triple-negative breast cancer
TNBC is the most aggressive BC subtype in 
addition to HER2, a tumor loaded with many mu-
tations and thus genomic instability, the result of 
which is a multitude of tumor neo-antigens, mak-
ing TNBC the most immunogenic BC. This ex-
plains the highest prevalence of lymphocytic infil-
trate in TNBC, as well as the highest incidence of 
LPBC among this type of BC (44,30). Research into 
the role of TILs in BC has so far yielded the most 
significant results in the TNBC population. A se-
ries of studies and meta-analyzes have demon-
strated the possible association of TILs with prog-
nosis in TNBC (29,33,34,41,42,45). Results relate to 
the impact of TILs on improved disease-free sur-
vival (DFS), overall survival (OS), survival with-
out distant dissemination (DDFS), reduction of 
disease recurrence locally and remotely (45). This 
favorable prognostic impact of TILs has been 
shown to be independent of age, lymph node sta-
tus, tumor size and histologic grade, peritumor 
vascular invasion, or Ki67 proliferation index (40). 
Further subdivision of TNBC into core - basal type 
(CBP) and 5NP revealed no significant difference 
in the clinical value of TILs expression. Some stud-
ies have shown that there is no statistically signifi-
cant effect on OS in 5NPs, however relevant data 
for the 5NP population is scarce (46,45). Despite 
the different and in some studies conflicting re-
sults of the prognostic value of IHC analyzed sep-
arately for different subpopulations of TILs (CD8 
+, FOXP3 +), pooled analyzes show that there is 
really no enough strong data to support the exis-
tence of this difference in clinical value (45). Like-
wise, according to some studies, the prognostic 
value of TILs in TNBC seem to be more significant 
if analyzed without the influence of chemothera-
py: HR (hazard ratio) for OS in TIL-rich tumors in 
the presence of chemotherapy was found to be 
lower in compared to that without chemotherapy 
(46), but several studies and pooled multivariate 
analyzes have shown that TILs are a good inde-
pendent predictive indicator of response to che-
motherapy (31,35,47,48,49). As mentioned above, 
the presence of TILs in a pre-therapeutic biopsy 
specimen may predict good response to therapy 
and the achievement of pCR (50,51), and the pres-
ence of TILs in the residual tumor tissue, follow-
ing treatment, is also a prognostic indicator of bet-
ter metastasis-free survival and overall survival 
(52,53). Finally, enhanced expression of PD1 and 
PDL1 was demonstrated on activated immune 
cells, much more than on tumor cells, in TIL-rich 
TNBC (54,55). This signaling pathway is known to 
be the target of today’s immunotherapy approach-
es with checkpoint inhibitors, such as already 
mentioned pembrolizumab and atezolizumab, al-
though with different ways of evaluation of PDL1 
positivity (from PDL1 positive immune cells ex-
clusively, for atezolizumab, to combined positive 
score, of immune and tumor cells, carrying PDL1, 
among all cells, for pembrolizumab). Role of PDL1 
positivity was crucial in these trials, and only the 
PDL1 positive tumors responded, yet significantly 
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more and better in those trials where immuno-
therapy was combined with chemotherapy 
(12,13,56). Therefore, TILs in TNBC, as an indirect 
indicator of PDL1 expression, is seriously consid-
ered for use as a marker in routine clinical practice 
for its ease and cost-effectiveness of detection.
CONCLUSION
Therapeutic potential of the immune system-
tumor interaction is truly great. The use of this po-
tential has shifted from initial unselective attempts 
to exploit the immune system, to more natural in-
terventions and release of an intrinsic immune re-
sponse, such as blocking immune inhibitory 
checkpoints. The success of such an approach ap-
pears to be more likely in the presence of indica-
tors of intrinsic immune response activity, which 
is an immune infiltrate in the tumor. Understand-
ing the origin, composition and function of the im-
mune infiltrate in a tumor is the basis for more ac-
curate assessment and prediction of the success of 
immunotherapy in the fight against cancer.
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Sažetak
IMUNITET I RAK: ULOGA TUMOR-INFILTRIRAJUĆIH LIMFOCITA  
KOD TROSTRUKO NEGATIVNOG KARCINOMA DOJKE
A. Tečić Vuger, R. Šeparović, Lj. Vazdar, M. Pavlović, P. Linarić, S. Šitić, M. Šepetavc i D. Vrbanec
Tumor stimulira specifične urođene i stečene imunološke mehanizme. Glavni nositelji imunološkog odgovora tijela na 
tumor su T limfociti, a glavni mehanizam je ubijanje tumorskih stanica citotoksičnim T limfocitima CD8 +. U nekim slučaje-
vima imunološki sustav također može imati protumorsku ulogu, što je paradoks, s obzirom na to da je poznato da upalno 
stanje potiče rast tumora. Jedna od glavnih karakteristika tumora je izbjegavanje imunološkog odgovora, posebno mehaniz-
mima inhibicije aktivnog antitumorskog imunološkog odgovora putem dva glavna fiziološka inhibitorna signala, CTLA-4 i 
PD1 / PDL1. Blokada ovih kontrolnih točaka, koji su mehanizmi inhibicije T stanica, nedavno je dala najbolje rezultate u 
imunoterapijskom pristupu liječenju karcinoma. Imuni infiltrat u tumoru, kao dokaz postojanja aktivnog unutarnjeg odgo-
vora organizma, je heterogen, a sastav se često razlikuje između različitih tumora i tumorskih stanica i uglavnom se dijeli 
na dvije glavne stanične linije: limfoidnu i mijeloidnu. O vrsti staničnih linija u imunološkom infiltratu i njihovoj aktivaciji i 
orijentaciji ovisi klinički odgovor kod različitih tumora. Dobro je poznato da imuni infiltrat, posebno limfociti koji infiltrira-
ju tumor (TIL), mogu predvidjeti odgovor na terapiju i imati prognostičku ulogu. Kod nekih solidnih tumora oni su dobar 
znak, dok kod nekih signaliziraju lošiju prognozu. Brojne studije procjenjivale su ulogu limfocitnog infiltrata u raku dojke 
(BC), a na temelju tog znanja uspostavljen je prvi koncenzus o standardizaciji procjene TIL u solidnim tumorima na BC 
modelu. Prognostičkoj ulozi TIL u trostruko negativnom raku dojke posvećeno je najviše pažnje.
KLJUČNE RIJEČI: antitumorski imunološki odgovor, tumor infiltrirajući limfociti, imunoterapija, trostruko negativni rak dojke
